β1,3-Galactosyltransferases-4/5 are novel tumor markers for gynecological cancers

Akira Seko, Fumio Kataoka, Daisuke Aoki, Masaru Sakamoto, Toshiaki Nakamura, Masayuki Hatae, Suguru Yonezawa, Katsuko Yamashita

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/Aims: While the CA 125 and SCC antigens are used as tumor markers for ovarian cancer and uterine cervical cancer, respectively, an effective marker for uterine corpus cancer has not been identified. We asked whether β1,3-galactosyltransferase-4 and/or 5 (β3Gal-T4/T5) could serve as novel tumor markers for detecting gynecological carcinomas, especially those of the uterine corpus. Methods: We obtained a monoclonal antibody and a polyclonal antiserum against β3Gal-T5 and constructed a sandwich ELISA method. Western blot analysis and immunoprecipitation revealed that this ELISA recognizes both β3Gal-T4 and β3Gal-T5. Results: We found β3Gal-T4 and T5 enzymatic activity in ovarian cancer tissues, indicating that these enzymes are expressed at least in ovarian cancer. The cutoff value was determined by ROC analysis to be 5.4 ng/ml in the sera. The β3Gal-T4/T5- positive rates for the sera from ovarian cancer and uterine cervical cancer patients were comparable with the CA 125- and SCC antigen-positive rates for these cancers, respectively. Significantly, the β3Gal-T4/T5-positive rate was higher for uterine corpus cancer (64%) than the CA 125 (37%)- and CA 19-9 (24%)-positive rates. The stage I uterine corpus cancers had particularly high β3Gal-T4/T5-positive rates (57%). Conclusion: β3Gal-T4/T5 is a novel tumor marker for uterine corpus cancer and other gynecological cancers.

Original languageEnglish
Pages (from-to)43-50
Number of pages8
JournalTumor Biology
Volume30
Issue number1
DOIs
Publication statusPublished - 2009 Apr

Fingerprint

Galactosyltransferases
Uterine Neoplasms
Tumor Biomarkers
Ovarian Neoplasms
CA-125 Antigen
Uterine Cervical Neoplasms
Neoplasms
Enzyme-Linked Immunosorbent Assay
Serum
Immunoprecipitation
ROC Curve
Immune Sera
Western Blotting
Monoclonal Antibodies
Carcinoma
Enzymes
squamous cell carcinoma-related antigen

Keywords

  • β1,3-Galactosyltransferase
  • Ovarian cancer
  • Sandwich ELISA
  • Tumor marker
  • Uterine corpus cancer

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)

Cite this

β1,3-Galactosyltransferases-4/5 are novel tumor markers for gynecological cancers. / Seko, Akira; Kataoka, Fumio; Aoki, Daisuke; Sakamoto, Masaru; Nakamura, Toshiaki; Hatae, Masayuki; Yonezawa, Suguru; Yamashita, Katsuko.

In: Tumor Biology, Vol. 30, No. 1, 04.2009, p. 43-50.

Research output: Contribution to journalArticle

Seko, A, Kataoka, F, Aoki, D, Sakamoto, M, Nakamura, T, Hatae, M, Yonezawa, S & Yamashita, K 2009, 'β1,3-Galactosyltransferases-4/5 are novel tumor markers for gynecological cancers', Tumor Biology, vol. 30, no. 1, pp. 43-50. https://doi.org/10.1159/000203129
Seko, Akira ; Kataoka, Fumio ; Aoki, Daisuke ; Sakamoto, Masaru ; Nakamura, Toshiaki ; Hatae, Masayuki ; Yonezawa, Suguru ; Yamashita, Katsuko. / β1,3-Galactosyltransferases-4/5 are novel tumor markers for gynecological cancers. In: Tumor Biology. 2009 ; Vol. 30, No. 1. pp. 43-50.
@article{eafabca5893b4146a997940816ced4b5,
title = "β1,3-Galactosyltransferases-4/5 are novel tumor markers for gynecological cancers",
abstract = "Background/Aims: While the CA 125 and SCC antigens are used as tumor markers for ovarian cancer and uterine cervical cancer, respectively, an effective marker for uterine corpus cancer has not been identified. We asked whether β1,3-galactosyltransferase-4 and/or 5 (β3Gal-T4/T5) could serve as novel tumor markers for detecting gynecological carcinomas, especially those of the uterine corpus. Methods: We obtained a monoclonal antibody and a polyclonal antiserum against β3Gal-T5 and constructed a sandwich ELISA method. Western blot analysis and immunoprecipitation revealed that this ELISA recognizes both β3Gal-T4 and β3Gal-T5. Results: We found β3Gal-T4 and T5 enzymatic activity in ovarian cancer tissues, indicating that these enzymes are expressed at least in ovarian cancer. The cutoff value was determined by ROC analysis to be 5.4 ng/ml in the sera. The β3Gal-T4/T5- positive rates for the sera from ovarian cancer and uterine cervical cancer patients were comparable with the CA 125- and SCC antigen-positive rates for these cancers, respectively. Significantly, the β3Gal-T4/T5-positive rate was higher for uterine corpus cancer (64{\%}) than the CA 125 (37{\%})- and CA 19-9 (24{\%})-positive rates. The stage I uterine corpus cancers had particularly high β3Gal-T4/T5-positive rates (57{\%}). Conclusion: β3Gal-T4/T5 is a novel tumor marker for uterine corpus cancer and other gynecological cancers.",
keywords = "β1,3-Galactosyltransferase, Ovarian cancer, Sandwich ELISA, Tumor marker, Uterine corpus cancer",
author = "Akira Seko and Fumio Kataoka and Daisuke Aoki and Masaru Sakamoto and Toshiaki Nakamura and Masayuki Hatae and Suguru Yonezawa and Katsuko Yamashita",
year = "2009",
month = "4",
doi = "10.1159/000203129",
language = "English",
volume = "30",
pages = "43--50",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - β1,3-Galactosyltransferases-4/5 are novel tumor markers for gynecological cancers

AU - Seko, Akira

AU - Kataoka, Fumio

AU - Aoki, Daisuke

AU - Sakamoto, Masaru

AU - Nakamura, Toshiaki

AU - Hatae, Masayuki

AU - Yonezawa, Suguru

AU - Yamashita, Katsuko

PY - 2009/4

Y1 - 2009/4

N2 - Background/Aims: While the CA 125 and SCC antigens are used as tumor markers for ovarian cancer and uterine cervical cancer, respectively, an effective marker for uterine corpus cancer has not been identified. We asked whether β1,3-galactosyltransferase-4 and/or 5 (β3Gal-T4/T5) could serve as novel tumor markers for detecting gynecological carcinomas, especially those of the uterine corpus. Methods: We obtained a monoclonal antibody and a polyclonal antiserum against β3Gal-T5 and constructed a sandwich ELISA method. Western blot analysis and immunoprecipitation revealed that this ELISA recognizes both β3Gal-T4 and β3Gal-T5. Results: We found β3Gal-T4 and T5 enzymatic activity in ovarian cancer tissues, indicating that these enzymes are expressed at least in ovarian cancer. The cutoff value was determined by ROC analysis to be 5.4 ng/ml in the sera. The β3Gal-T4/T5- positive rates for the sera from ovarian cancer and uterine cervical cancer patients were comparable with the CA 125- and SCC antigen-positive rates for these cancers, respectively. Significantly, the β3Gal-T4/T5-positive rate was higher for uterine corpus cancer (64%) than the CA 125 (37%)- and CA 19-9 (24%)-positive rates. The stage I uterine corpus cancers had particularly high β3Gal-T4/T5-positive rates (57%). Conclusion: β3Gal-T4/T5 is a novel tumor marker for uterine corpus cancer and other gynecological cancers.

AB - Background/Aims: While the CA 125 and SCC antigens are used as tumor markers for ovarian cancer and uterine cervical cancer, respectively, an effective marker for uterine corpus cancer has not been identified. We asked whether β1,3-galactosyltransferase-4 and/or 5 (β3Gal-T4/T5) could serve as novel tumor markers for detecting gynecological carcinomas, especially those of the uterine corpus. Methods: We obtained a monoclonal antibody and a polyclonal antiserum against β3Gal-T5 and constructed a sandwich ELISA method. Western blot analysis and immunoprecipitation revealed that this ELISA recognizes both β3Gal-T4 and β3Gal-T5. Results: We found β3Gal-T4 and T5 enzymatic activity in ovarian cancer tissues, indicating that these enzymes are expressed at least in ovarian cancer. The cutoff value was determined by ROC analysis to be 5.4 ng/ml in the sera. The β3Gal-T4/T5- positive rates for the sera from ovarian cancer and uterine cervical cancer patients were comparable with the CA 125- and SCC antigen-positive rates for these cancers, respectively. Significantly, the β3Gal-T4/T5-positive rate was higher for uterine corpus cancer (64%) than the CA 125 (37%)- and CA 19-9 (24%)-positive rates. The stage I uterine corpus cancers had particularly high β3Gal-T4/T5-positive rates (57%). Conclusion: β3Gal-T4/T5 is a novel tumor marker for uterine corpus cancer and other gynecological cancers.

KW - β1,3-Galactosyltransferase

KW - Ovarian cancer

KW - Sandwich ELISA

KW - Tumor marker

KW - Uterine corpus cancer

UR - http://www.scopus.com/inward/record.url?scp=60449117630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60449117630&partnerID=8YFLogxK

U2 - 10.1159/000203129

DO - 10.1159/000203129

M3 - Article

C2 - 19225246

AN - SCOPUS:60449117630

VL - 30

SP - 43

EP - 50

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 1

ER -